# A Study To Evaluate D1 Receptor Occupancy (RO) Following Single Dose of PF-06412562 In Healthy Male Volunteers

> **NCT02124213** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 5 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** 30 mg PF-06412562
- **DRUG:** PF-06412562
- **DRUG:** PF-06412562

## Key facts

- **NCT ID:** NCT02124213
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09
- **Primary completion:** 2014-10
- **Final completion:** 2014-10
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2014-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02124213

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02124213, "A Study To Evaluate D1 Receptor Occupancy (RO) Following Single Dose of PF-06412562 In Healthy Male Volunteers". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT02124213. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*